We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Immunovia Ab (publ) | LSE:0G8X | London | Ordinary Share | SE0006091997 | IMMUNOVIA ORD SHS |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 191.40 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Surgical,med Instr,apparatus | 1.8M | -309.44M | -6.8328 | -0.02 | 6.79M |
From Apr 2019 to Apr 2024
LUND, Sweden, Feb. 14, 2019 /PRNewswire/ --
Immunovia AB today announced that Mats Grahn, Chief Executive Officer, will participate and host one-on-one investor meetings at the following upcoming investor conferences:
Carnegie Healthcare Seminar 2019 in Stockholm, Sweden
Tuesday, March 5, 2019
ROTH Capital's 31st Annual Investor Conference in Dana Point, CA, USA
March 17th– 19th, 2019
Vator Securities Unicorn Summit in Stockholm, Sweden
Thursday, March 21, 2019
For details, please check: https://immunovia.com/investors/calendar/
For more information, please contact:
Julie Silber
Director of Investor Relations
Email: julie.silber@immunovia.com
Tel: +46-7-93-486-277
About Immunovia
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia's strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. (Source: www.immunovia.com)
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.
This information was brought to you by Cision http://news.cision.com
http://news.cision.com/immunovia-ab/r/immunovia-to-participate-in-upcoming-investor-conferences-in-march,c2741721
The following files are available for download:
https://mb.cision.com/Main/13121/2741721/991516.pdf | Immunovia, PR coming events |
View original content:http://www.prnewswire.com/news-releases/immunovia-to-participate-in-upcoming-investor-conferences-in-march-300795959.html
SOURCE Immunovia AB
Copyright 2019 PR Newswire
1 Year Immunovia Ab (publ) Chart |
1 Month Immunovia Ab (publ) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
